Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls

Journal of Bone and Mineral Research

Volumn 28, Issue 1, 2013, Pages 162-168

  Güerri Fernández, Roberto C ^a,b   Nogués, Xavier ^a,b   Quesada Gõmez, José M ^b,c   Torres Del Pliego, Elisa ^a,b   Puig, Lluís ^a   García Giralt, Natalia ^a   Yoskovitz, Guy ^a   Mellibovsky, Leonardo ^a,b   Hansma, Paul K ^d   Díez Pérez, Adolfo ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ATYPICAL FRACTURES; BONE QUALITY; MICROINDENTATION

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; ATYPICAL FEMORAL FRACTURE; BONE DENSITOMETRY; BONE EXAMINATION; BONE TISSUE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR FRACTURE; FRAGILITY FRACTURE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MICROINDENTATION; OUTCOME ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE DENSITY; CASE-CONTROL STUDIES; FEMALE; FEMORAL FRACTURES; HUMANS; MALE; MIDDLE AGED; ORTHOPEDICS;

EID: 84872865692     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1731     Document Type: Article

References (39)

1. Sellmeyer DE,. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010 Oct 6; 304 (13): 1480-4.
2. Schilcher J, Michaelsson K, Aspenberg P,. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011 May 5; 364 (18): 1728-37.
3. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A,. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011 Feb 23; 305 (8): 783-9.
4. Yli-Kyyny TT, Tamminen I, Kroger H,. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2010 Dec; 33 (12): 867.
5. Bauer DC,. Bisphosphonate use and atypical femoral fractures: getting down to brass tacks. J Clin Endocrinol Metab. 2010 Dec; 95 (12): 5207-529.
6. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC,. Fracture Intervention Trial Steering Committee, HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010 May 13; 362 (19): 1761-71.
7. Girgis CM, Sher D, Seibel MJ,. Atypical femoral fractures and bisphosphonate use. N Engl J Med. 2010 May 13; 362 (19): 1848-9.
8. Giusti A, Hamdy NA, Papapoulos SE,. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010 Aug; 47 (2): 169-80.
9. Abrahamsen B, Eiken P, Eastell R,. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009 Jun; 24 (6): 1095-102.
10. Ali T, Jay RH,. Spontaneous femoral shaft fracture after long-term alendronate. Age Ageing. 2009 Sep; 38 (5): 625-6.
11. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C,. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation working group report. Osteoporos Int. 2011 Feb; 22 (2): 373-90.
12. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M,. American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010 Nov; 25 (11): 2267-94.
13. Ahlman MA, Rissing MS, Gordon L,. Case review: evolution of bisphosphonate-related atypical fracture retrospectively observed with DXA scanning. J Bone Miner Res. 2012 Feb; 27 (2): 496-8.
14. McKiernan FE,. Atypical femoral diaphyseal fractures documented by serial DXA. J Clin Densitom. 2010 Jan-Mar; 13 (1): 102-3.
15. Bala Y, Farlay D, Chapurlat RD, Boivin G,. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur J Endocrinol. 2011 Oct; 165 (4): 647-55.
16. Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP,. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone. 2011 Dec; 49 (6): 1279-89.
17. Diez-Perez A, Guerri R, Nogues X, Caceres E, Pena MJ, Mellibovsky L, Randall C, Bridges D, Weaver JC, Proctor A, Brimer D, Koester KJ, Ritchie RO, Hansma PK,. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res. 2010 Aug; 25 (8): 1877-85.
18. Schott AM, Weill-Engerer S, Hans D, Duboeuf F, Delmas PD, Meunier PJ,. Ultrasound discriminates patients with hip fracture equally well as dual-energy X-ray absorptiometry and independently of bone mineral density. J Bone Miner Res. 1995 Feb; 10 (2): 243-9.
19. Pulkkinen P, Partanen J, Jalovaara P, Jämsä T,. Combination of bone mineral density and upper femur geometry improves the prediction of hip fracture. Osteoporos Int. 2004; Apr; 15 (4): 274-80.
20. Boehm HF, Vogel T, Panteleon A, Burklein D, Bitterling H, Reiser M,. Differentiation between post-menopausal women with and without hip fractures: enhanced evaluation of clinical DXA by topological analysis of the mineral distribution in the scan images. Oteoporos Int. 2007 Jun; 18 (6): 779-87.
21. Lenart BA, Lorich DG, Lane JM,. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008 Mar 20; 358 (12): 1304-6.
22. Schilcher J, Aspenberg P,. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009 Aug; 80 (4): 413-5.
23. Gibson MV,. Evaluation and treatment of bone disease after fragility fracture. Geriatrics. 2008 Jul; 63 (7): 21-30.
24. Goddard MS, Reid KR, Johnston JC, Khanuja HS,. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2009 Aug; 32 (8).
25. Gunawardena I, Baxter M, Rasekh Y,. Bisphosphonate-related subtrochanteric femoral fractures. Am J Geriatr Pharmacother. 2011 Jun; 9 (3): 194-8.
26. Cheung RK, Leung KK, Lee KC, Chow TC,. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007 Dec; 13 (6): 485-9.
27. Salminen S, Pihlajamaki H, Avikainen V, Kyro A, Bostman O,. Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma. 1997 Jul; 43 (1): 117-22.
28. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS,. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury. 2008; Feb; 39 (2): 224-31.
29. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH,. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011 May; 26 (5): 993-1001.
30. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE,. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011 May 1; 48 (5): 966-71.
31. Fantner GE, Hassenkam T, Kindt JH, Weaver JC, Birkedal H, Pechenik L, Cutroni JA, Cidade GA, Stucky GD, Morse DE, Hansma PK,. Sacrificial bonds and hidden length dissipate energy as mineralized fibrils separate during bone fracture. Nat Mater. 2005 Aug; 4 (8): 612-6.
32. Fantner GE, Oroudjev E, Schitter G, Golde LS, Thurner P, Finch MM, Turner P, Gutsmann T, Morse DE, Hansma H, Hansma PK,. Sacrificial bonds and hidden length: unraveling molecular mesostructures in tough materials. Biophys J. 2006 Feb 15; 90 (4): 1411-8.
33. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY,. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005 Mar; 90 (3): 1294-301.
34. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D,. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009 Jul; 85 (1): 37-44.
35. Unnanuntana A, Ashfaq K, Ton QV, Kleimeyer JP, Lane JM,. The effect of long-term alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res. 2012 Jan; 470 (1): 291-8.
36. Tan SC, Koh SB, Goh SK, Howe TS,. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int. 2011 Jul; 22 (7): 2211-2.
37. Yates CJ, Bartlett MJ, Ebeling PR,. An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature. J Bone Miner Res. 2011 Jun; 26 (6): 1377-9.
38. Whyte MP,. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res. 2009 Jun; 24 (6): 1132-4.
39. Visekruna M, Wilson D, McKiernan FE,. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008 Aug; 93 (8): 2948-52.